Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Fabre

Showing results (21-30 of 72) with videos related to

Pageof 8
Sort By:
Thoracic Cancer|November 12, 2015
Evolution of induction chemotherapy for non-small cell lung cancer over the last 30 years: A surgical appraisalElizabeth Fabre, Caroline Rivera, Pierre Mordant, et al.
Bulletin Du Cancer|January 22, 2016
[What future for circulating tumor DNA? Current data and prospects in colorectal, non-small cell lung and pancreatic cancers]Daniel Pietrasz, Nicolas Pécuchet, Elizabeth Fabre, et al.
Cancer|May 12, 2006
Retroperitoneal liposarcomas: follow-up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomasElizabeth Fabre-Guillevin, Jean-Michel Coindre, Nicolas de Saint Aubain Somerhausen, et al.
Lung Cancer (Amsterdam, Netherlands)|June 18, 2013
High grade neuroendocrine lung tumors: pathological characteristics, surgical management and prognostic implicationsBertrand Grand, Aurélie Cazes, Pierre Mordant, et al.
Comptes Rendus Biologies|November 28, 2006
[The PAI-1 swing: microenvironment and cancer cell migration]Michel Malo, Cécile Charrière-Bertrand, Chafika Chettaoui, et al.
Respiratory Medicine and Research|February 21, 2026
Efficacy and safety of second-line treatments in patients with advanced EGFR-mutated non-small cell lung cancer progressing on osimertinib without identified targetable resistance mechanism at progressionPaul Lajoinie, Vincent Fallet, Marie Wislez, et al.
Frontiers in Immunology|October 31, 2022
CXCR6 expressing T cells: Functions and role in the control of tumorsNesrine Mabrouk, Thi Tran, Ikuan Sam, et al.
Bulletin Du Cancer|March 9, 2023
Safety and efficacy of immunotherapy according to the age threshold of 80 yearsSoraya Mebarki, Frédéric Pamoukdjian, Monica Pierro, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 12, 2011
DeltaN TP63 reactivation, epithelial phenotype maintenance, and survival in lung squamous cell carcinomaKarine Pallier, Aurélie Cazes, Laila El Khattabi, et al.
BMC Medical Genomics|June 14, 2008
Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinomaHélène Blons, Karine Pallier, Delphine Le Corre, et al.
Pageof 8

Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
Thoracic Cancer|November 12, 2015
Evolution of induction chemotherapy for non-small cell lung cancer over the last 30 years: A surgical appraisalElizabeth Fabre, Caroline Rivera, Pierre Mordant, et al.
Bulletin Du Cancer|January 22, 2016
[What future for circulating tumor DNA? Current data and prospects in colorectal, non-small cell lung and pancreatic cancers]Daniel Pietrasz, Nicolas Pécuchet, Elizabeth Fabre, et al.
Cancer|May 12, 2006
Retroperitoneal liposarcomas: follow-up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomasElizabeth Fabre-Guillevin, Jean-Michel Coindre, Nicolas de Saint Aubain Somerhausen, et al.
Lung Cancer (Amsterdam, Netherlands)|June 18, 2013
High grade neuroendocrine lung tumors: pathological characteristics, surgical management and prognostic implicationsBertrand Grand, Aurélie Cazes, Pierre Mordant, et al.
Comptes Rendus Biologies|November 28, 2006
[The PAI-1 swing: microenvironment and cancer cell migration]Michel Malo, Cécile Charrière-Bertrand, Chafika Chettaoui, et al.
Respiratory Medicine and Research|February 21, 2026
Efficacy and safety of second-line treatments in patients with advanced EGFR-mutated non-small cell lung cancer progressing on osimertinib without identified targetable resistance mechanism at progressionPaul Lajoinie, Vincent Fallet, Marie Wislez, et al.
Frontiers in Immunology|October 31, 2022
CXCR6 expressing T cells: Functions and role in the control of tumorsNesrine Mabrouk, Thi Tran, Ikuan Sam, et al.
Bulletin Du Cancer|March 9, 2023
Safety and efficacy of immunotherapy according to the age threshold of 80 yearsSoraya Mebarki, Frédéric Pamoukdjian, Monica Pierro, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 12, 2011
DeltaN TP63 reactivation, epithelial phenotype maintenance, and survival in lung squamous cell carcinomaKarine Pallier, Aurélie Cazes, Laila El Khattabi, et al.
BMC Medical Genomics|June 14, 2008
Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinomaHélène Blons, Karine Pallier, Delphine Le Corre, et al.
Pageof 8